pemigatinib 13.5 MG Oral Tablet [Pemazyre]

Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.

Start free with Eleplan

Clinical drug

pemigatinib 13.5 MG Oral Tablet [Pemazyre]

13.5 MG · Oral Tablet · oral

A form of pemigatinib →

pemigatinib 13.5 MG Oral Tablet [Pemazyre] — Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors. Strength, form, class, interactions & more.

pemigatinib 13.5 MG Oral Tablet [Pemazyre]

Active ingredient

pemigatinib →

Classification

Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitorsKinase Inhibitor

Drug interactions

Pemigatinib has significant interactions with CYP3A inducers and inhibitors.

  • majorstrong and moderate CYP3A inducers — decreases pemigatinib plasma concentrations, which may reduce efficacy
  • majorstrong and moderate CYP3A inhibitors — increases pemigatinib plasma concentrations, which may increase the incidence and severity of adverse reactions

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.

Get started freeSee how Eleplan works →